Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st New Schizophrenia Drug in Decades
FDA Approves the First New Schizophrenia Drug in Decades
No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder.
BMS wins approval for schizophrenia drug acquired from Karuna
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.
STAT
11h
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
health.wusf.usf.edu
57m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
FiercePharma
1d
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
9h
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
C&EN
1d
FDA approves Cobenfy, a first-in-class schizophrenia drug
The drug was developed by
Karuna
Therapeutics
, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion. This is the first new class of treatment for the psychiatric disorder since ...
Medscape
10h
FDA OKs First-in-Class Antipsychotic for Schizophrenia
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
ENDPOINTS NEWS
1d
Endpoints 11 winner Seaport Therapeutics: The Karuna team is back with another big bet in neuroscience
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Cobenfy
Food and Drug Administration
Bristol-Myers Squibb
FDA
Feedback